WallStSmart
ITRM

Iterum Therapeutics PLC

NASDAQ: ITRM · HEALTHCARE · BIOTECHNOLOGY

$0.03
+0.00% today

Updated 2026-06-05

Market cap
$3.75M
P/E ratio
P/S ratio
9.62x
EPS (TTM)
$-0.72
Dividend yield
52W range
$0 – $1
Volume
188.4M

Iterum Therapeutics PLC (ITRM) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
-1,982.00%
ROE
-556.00%
ROA
-53.30%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2016$0.00$-13.46M
2017$508000.00$-29.41M100.00%-5,798.23%-5,788.58%
2018$869000.00$-77.06M100.00%-8,810.01%-8,867.20%
2019$37000.00$-103.13M100.00%-275,732.43%-278,729.73%
2020$0.00$-52.01M
2021$0.00$-91.56M
2022$0.00$-44.43M
2023$0.00$-38.37M
2024$0.00$-24.77M

Frequently asked questions

What is Iterum Therapeutics PLC's revenue?

Iterum Therapeutics PLC's trailing twelve-month revenue is $390000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does ITRM generate?

ITRM produced $-26.77M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.